BIOAGE Labs Inc
NASDAQ:BIOA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BIOAGE Labs Inc
NASDAQ:BIOA
|
US |
|
B
|
Base Carbon Inc
NEO:BCBN
|
CA |
|
Katare Spinning Mills Ltd
BSE:502933
|
IN |
|
H
|
Hengyang Petrochemical Logistics Ltd
SGX:5PD
|
CN |
|
I
|
Inchcape PLC
DUS:IJCA
|
UK |
|
ERF Wireless Inc
OTC:ERFB
|
US |
|
A
|
Abacus Storage King
ASX:ASK
|
AU |
BIOAGE Labs Inc
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Richmond California, California. The company went IPO on 2024-09-26. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. The company has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Richmond California, California. The company went IPO on 2024-09-26. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. The company has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
